|
|
|
Volumn 25, Issue 12, 2011, Pages 1212-1213
|
|
AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BISPHOSPHONIC ACID DERIVATIVE;
BONE DENSITY CONSERVATION AGENT;
IMIDAZOLE DERIVATIVE;
ZOLEDRONIC ACID;
ARTICLE;
BREAST TUMOR;
DISEASE FREE SURVIVAL;
FEMALE;
HUMAN;
MORTALITY;
POSTMENOPAUSE;
BONE DENSITY CONSERVATION AGENTS;
BREAST NEOPLASMS;
DIPHOSPHONATES;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
IMIDAZOLES;
POSTMENOPAUSE;
|
|
EID: 84856603147
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|